Aberdeen Group plc Takes Position in Indivior PLC $INDV

Aberdeen Group plc acquired a new position in Indivior PLC (NASDAQ:INDV) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 160,717 shares of the company’s stock, valued at approximately $3,875,000.

Other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after purchasing an additional 1,299,425 shares during the period. Jane Street Group LLC raised its position in shares of Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in shares of Indivior during the second quarter valued at about $262,000. Y Intercept Hong Kong Ltd lifted its stake in shares of Indivior by 17.4% in the second quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock valued at $375,000 after buying an additional 3,769 shares during the period. Finally, Amalgamated Bank bought a new stake in shares of Indivior in the second quarter valued at about $61,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on INDV shares. Northland Securities set a $50.00 price target on Indivior in a research note on Tuesday, January 20th. HC Wainwright lifted their price objective on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Craig Hallum restated a “buy” rating and set a $41.00 price objective on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley restated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 target price (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Indivior has an average rating of “Moderate Buy” and an average target price of $39.33.

Indivior Price Performance

Shares of NASDAQ:INDV opened at $33.89 on Friday. The business’s fifty day moving average price is $34.77 and its two-hundred day moving average price is $29.60. Indivior PLC has a fifty-two week low of $7.62 and a fifty-two week high of $38.00. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of 36.84 and a beta of 0.80.

Insiders Place Their Bets

In other news, Director Daniel A. Ninivaggi bought 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director directly owned 16,923 shares of the company’s stock, valued at $598,904.97. This trade represents a 4.80% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Mark Stejbach purchased 775 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director directly owned 16,847 shares in the company, valued at $596,215.33. The trade was a 4.82% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 4,871 shares of company stock worth $172,385 in the last quarter.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.